{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-258780","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.922381+00:00","generated_at":"2026-05-17T01:20:45.865786+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"DBV Technologies appoints Philina Lee to Board of Directors effective October 30, 2025","bullets":["Lee replaces Daniel Soland; appointment subject to shareholder ratification at next annual meeting.","She previously served as Chief Commercial Officer of Blueprint Medicines, leading AYVAKIT launch.","Lee will serve on the Compensation Committee of the Board.","She will receive an annual retainer of €100,000 plus €5,000 for committee service.","Company now has ten board members; Lee brings biopharma commercialization experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-258780","json":"https://secwatch.observer/filing/0001193125-25-258780.json","markdown":"https://secwatch.observer/filing/0001193125-25-258780.md","text":"https://secwatch.observer/filing/0001193125-25-258780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312525258780/0001193125-25-258780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312525258780/d82861d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:20:45.865786+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}